VTVT · vTv Therapeutics Inc.
$31.94
+0.86 (+2.77%)
At close · Jul 29
Market Cap
$122.42M
Shares
3.94M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.08
Open$31.97
Day$29.44–32.03
52W$14.00–44.00
Avg vol 30d73K
Short int172K · 4.4% float · 2.8d
Short vol53%
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
−8%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
57%
mid-range
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−19%
trailing
YTD return
−22%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $34 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
5 of 35 funds reported for Jun 30 · net +2.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.37% of float · ▲ +5.2% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-25.3M
Balance sheet
$86.8M
net cash
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $34 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
5 of 35 funds reported for Jun 30 · net +2.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.37% of float · ▲ +5.2% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $14
Now $31 · 57%
52-wk high $44
vs 200-day avg -6%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTVT
this stock
vTv Therapeutics Inc.
|
$122.42M | -22.3% | -100.0% | — | 4.4% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTVT | -4.0% | -11.4% | -18.9% | -17.5% | -22.3% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -3.0% | -11.4% | -26.3% | -16.7% | -30.9% |